Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: Metabolism and clinical practice

Current Drug Metabolism

Volumn 12, Issue 1, 2011, Pages 57-69

  Abe, Masanori ^a   Okada, Kazuyoshi ^a   Soma, Masayoshi ^a,b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Antidiabetic agent; Chronic kidney disease; Clinical practice; DPP 4 inhibitor; End stage renal disease; Metabolism; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; INCRETIN; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; SULFONYLUREA;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIABETIC PATIENT; DIALYSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; GLYCEMIC CONTROL; HUMAN; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CONCENTRATION-TIME CURVE;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; HALF-LIFE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 79951591247     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011794520053     Document Type: Article

References (132)

1. Cao, J. J.; Hudson, M.; Jankowski, M.; Whitehouse, F.; Weaver, W. D. Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus. Am. J. Cardiol., 2005, 96(2), 183-186. (Pubitemid 40978570)
2. Gaede, P.; Vedel, P.; Larsen, N.; Jensen, G.. V.; Parving, H. H.; Pedersen, O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med., 2003, 348(5), 383-393. (Pubitemid 36159355)
3. Garber, A. J. Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes. Obes. Metab., 2002, 4, S5-12. (Pubitemid 34285274)
4. Kassab, E.; McFarlane, S. I.; Sower, J. R. Vascular complications in diabetes and their prevention. Vasc. Med. 2001, 6(4), 249-255. (Pubitemid 34256766)
5. Colwell, J. A. Vascular thrombosis in type II diabetes mellitus. Diabetes, 1993, 42(1), 8-11. (Pubitemid 23013789)
6. Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney. Dis., 2007, 49(2), S62-S73.
7. Yu, C. C.; Wu, M. S.; Wu, C. H.; Young, C. W.; Huang, J. Y.; Hong, J. J.; Fan Cjiang, C. Y.; Leu, M. L.; Huang, C. C. Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit. Dial. Int., 1997, 17(3), 262-268.
8. Morioka, T.; Emoto, M.; Tabata, T.; Shoji, T.; Tahara, H.; Kishimoto, H.; Ishimura, E.; Nishizawa, Y. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care, 2001, 24(5), 909-913. (Pubitemid 33636068)
9. Yale, J. F. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J. Am. Soc. Nephrol., 2005, 16, 7-10.
10. Senekjian, H. O.; Lee, C. S.; Kuo, T. H.; Au, D. S.; Krothapalli, R. Absorption and disposition of ibuprofen in hemodialyzed uremic patients. Eur. J. Rheumatol. Inflam. 1983, 6(2), 155-162. (Pubitemid 14191440)
11. Zazgornik, J.; Huang, M. L.; Van Peer, A.; Woestenborghs, R.; Heykants, J.; Stephen, A. Pharmacokinetics of orally administered levocabastine in patients with renal insufficiency. J. Clin. Pharmacol., 1993, 32(12), 1214-1218. (Pubitemid 24023686)
12. Touchette, M. A.; Slaughter, R. L. The effect of renal failure on hepatic drug clearance. DICP, 1991, 25(11), 1214-1224.
13. Naud, J.; Michaud, J.; Leblond, F. A.; Bernier, G.; Bonnardeaux, A.; Pichette, V. Effects of chronic renal failure on liver drug transporters. Drug. Metab. Dispos., 2008, 36(1), 124-128.
14. Nolin, T. D.; Naud, J.; Leblond, F. A.; Pichette, V. Emerging evidence of impacy of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther., 2008, 83(6) 898-903. (Pubitemid 351704931)
15. Nolin, T. D.; Frye, R. F.; Matzke, G. R. Hepatic drug metabolism and transport in patients with kidney disease. Am. J. Kidney. Dis., 2003, 42(5), 906-925. (Pubitemid 37322908)
16. Sun, H.; Frassetto, L.; Benet, L. Z. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther., 2006, 109 (1-2), 1-11. (Pubitemid 41740811)
17. Salsburg, D. S. The UGDP study. JAMA, 1971, 218(11), 1704-1705.
18. United Kingdom Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352(9131), 837-853.
19. Zoungas, S.; de Galan, B. E.; Ninomiya, T.; Grobbee, D.; Hamet, P.; Heller, S.; MacMahon, S.; Marre, M.; Neal, B.; Patel, A.; Woodward, M.; Chalmers, J.; ADVANCE Collaborative Group; Cass, A.; Glasziou, P.; Harrap, S.; Lisheng, L.; Mancia, G.; Pillai, A.; Poulter, N.; Perkovic, V.; Travert, F. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care, 2009, 32(11), 2068-2074.
20. Rosenkranz, B.; Profozic, V.; Metelko, Z.; Mizljak, V.; Lange, C.; Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia, 1996, 39(12), 1617-1624. (Pubitemid 26397377)
21. Available from URL:http://www.pfizer.com/files/products/uspi-glipizide. pdf (Accessed October 1, 2010)
22. Kajosaari, L. I.; Laitila, J.; Neuvonen, P. J.; Backman, J. T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol., 2005, 97(4), 249-256. (Pubitemid 41433700)
23. Kajosaari, L. I.; Niemi, M.; Backman, J. T.; Neuvonen, P. J. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin. Pharmacol. Ther., 2006, 79(39), 231-242.
24. Niemi, M.; Backman, J. T.; Juntti-Patinen, L.; Neuvonen, M.; Neuvonen, P. J. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br. J. Clin. Pharmacol., 2005, 60(2), 208-217. (Pubitemid 41075907)
25. Murbury, T. C.; Ruckle, J. L.; Hatorp, V.; Andersen, M. P.; Nielsen, K. K.; Huang, W. X.; Strange, P. Pharmakokinetics of repaglinide in subjects with renal impairment. Clin. Pharmacol. Ther., 2000, 67(1), 7-15. (Pubitemid 30078382)
26. Yu, L.; Lu, S.; Lin, Y.; Zeng, S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem. Pharmacol., 2007, 73(11), 1842-1851. (Pubitemid 46601408)
27. Yu, L.; Lu, S.; Lin, Y.; Zeng, S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem. Pharmacol., 2007, 73, 1842-1851. (Pubitemid 46601408)
28. Reimann, F.; Proks, P.; Ashcroft, F. M. Effects of mitiglinide (S 21403) on Kir6.2/SURl, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br. J. Pharmacol., 2001, 132(7), 1542-1548. (Pubitemid 32281043)
29. Kaku, K.; Tanaka, S.; Origasa, H.; Kikuchi, M.; Akanuma, Y. Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: A randomized double blind trial. Endocr. J., 2009, 56(5), 657-664.
30. Kaku, K.; Tanaka, S.; Orisawa, H.; Kikuchi, M.; Akanuma, Y. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocr. J., 2009, 56(6), 739-746.
31. Gao, X. The mitiglinide versus nateglinide comparison group. Multicentre, double-blind, randomized study of mitiglinide comapared with nateglinide in type 2 diabetes mellitus patients in China. J. Int. Med. Res., 2009, 37(8), 812-821.
32. Abe, M.; Okada, K.; Maruyama, T.; Maruyama, N.; Maysumoto, K. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin. Pharmacother., 2010, 11(2), 169-176.
33. Abe, M.; Okada, K.; Maruyama, T.; Maruyama, N.; Maysumoto, K. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endcrine. J., 2010, 57(7), 581-588.
34. Chiasson, J. L.; Gomis, R.; Hanefeld, M.; Josse, R. G.; Karasik, A.; Laakso, M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care, 1998, 21(10), 1720-1725. (Pubitemid 28449814)
35. Chiasson, J. L.; Josse, R. G.; Gomis, R.; Hanefeld, M.; Karasik, A.; Laakso, M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 2003, 290(4), 486-494. (Pubitemid 37430502)
36. Abe, M.; Kikuchi, F.; Kaizu, K.; Matsumoto, K. Combination therapy of pioglitazone with vogliboseimproves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin. Nephrol, 2007, 68(5), 287-294. (Pubitemid 350047761)
37. Available from URL:http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2008/020482s023lbl.pdf (Accessed Jan 15, 2011).
38. Available from URL:http://www.pfizer.com/files/products/uspiglyset.pdf (Accessed Jan 15, 2011).
39. United Kingdom Prospective Diabetes Study Group (UKPDS). 13; Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. B. M. J., 1995, 310(6972), 83-88.
40. United Kingdom Prospective Diabetes Study Group (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352(9131), 854-865.
41. Bailey, C. J.; Turner, R. C. Metformin. N. Engl. J. Med., 1996, 334(9), 574-579. (Pubitemid 126537875)
42. Cusi, K.; Consoli, A.; DeFronzo, R. A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endo. Met., 1996, 81(11), 4059-4067. (Pubitemid 26380418)
43. Mamputu, J. C.; Wiernsperger, N. F.; Renier, G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab., 2003, 29 (4 Pt 2), 6S71-76. (Pubitemid 37187093)
44. Sirtori CR, Franceschini G, Galli-Kiele M, Galli G, Bondioli A, Conti F. Disposition of metformin (N, N-dimethylbiguanide) in man. Clin. Pharmacol. Ther., 1978, 24(6), 683-193.
45. Available from URL:http://www.sanofi-aventis.ca/products/en/glucophage. pdf (Accessed Jan 15, 2011).
46. Lalau, J. D.; Andrejak, M.; Moriniere, P.; Coevoet, B.; Debussche, X.; Westeel, P. F.; Fournier, A.; Quichaud, J. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin ekimination. Int. J. Clin. Pharmacol. Ther. Toxicol, 1989, 27(6), 285-288. (Pubitemid 19147149)
47. Wong, T. Y.; Szeto, C. C.; Chow, K. M.; Leung, C. B.; Lam, C. W.; Li, P. K. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am. J. Kidney Dis., 2005, 46(4), 713-719. (Pubitemid 41383950)
48. Campbell, I. W. The clinical significance of PPARy agonism. Curr. Mol. Med., 2005, 5(3), 349-363.
49. Shinohara, K.; Shoji, T.; Emoto, M.; Tahara, H.; Koyama, H.; Ishimura, E.; Miki, T.; Tabata, T.; Nishizawa, Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J. Am. Soc. Nephrol., 2002, 13(7), 1894-1900. (Pubitemid 34700615)
50. Ciaraldi, T. P.; Huber-Knudsen, K.; Hickman, M.; Olefsky, J. M. Regulation of glucose transport in culture muscle cells by novel hypoglycemic agents. Metabolism, 1995, 44(8), 976-982.
51. Spiegelman, B. M. PPAR-y: adipogenic regulator and thiazolidinedione receptor. Diabetes, 1998, 47(4), 507-514. (Pubitemid 28160438)
52. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005, 65(3), 385-411. (Pubitemid 40227460)
53. Snyder, R. W.; Berns, J. S. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin. Dial., 2004, 17(5), 365-370. (Pubitemid 39422090)
54. Cox, P. J.; Ryan, D. A.; Hollis, F. J.; Harris, A. M.; Miller, A. K.; Vousden, M.; Cowley, H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos., 2000, 28(7), 772-780. (Pubitemid 30470827)
55. Goldstein, B. J. Rosiglitazone. Int. J. Clin. Pract., 2000, 54(5), 333-337. (Pubitemid 30386644)
56. Thompson, C. K.; Zussman, B.; Miller, A. K.; Freed, M. I. Pharmakokinetics of rosiglitazone in patients with end stage renal disease. J. Int. Med. Res., 2002, 30(4), 391-399. (Pubitemid 34993563)
57. Budde, K.; Neumayer, H. H.; Fritsche, L.; Sulowicz, W.; Stompor, T.; Eckland, D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br. J. Clin. Pharmacol. 2003, 55(4), 368-374. (Pubitemid 36535367)
58. Abe, M.; Kikuchi, F.; Okada, K.; Matsumoto, K. Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis. Therap. Apher. Dial., 2009, 13(3), 238-239.
59. Nissen, S. E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356(24), 2457-2471. (Pubitemid 46919772)
60. Graham, D. J.; Hellstrom, R. O.; MaCurdy, T. E.; Ali, F.; Sholley, C.; Worrall, C.; Kelman, J. A. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA, 2010, 304(4), 411-418.
61. Dormandy, J. A.; Charbonnel, B.; Eckland, D. J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I. K.; Skene, A. M.; Tan, M. H.; Lefèbvre, P. J.; Murray, G. D.; Standl, E.; Wilcox, R. G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R. J.; Korányi, L.; Laakso, M.; Mokán, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet, 2005, 366(9493), 1279-1289. (Pubitemid 41416583)
62. Martens, F. M.; Visseren, F. L.; Lemay, J.; de Koning, E. J.; Rabelink, T. J. Metabolic and additional vascular effects of thiazolidinediones. Drugs, 2002, 62(10), 1463-1480. (Pubitemid 34804155)
63. Lin, S. H.; Lin, Y. F.; Kuo, S. W.; Hsu, Y. J.; Hung, Y. J. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am. J. Kid. Dis., 2003, 42(4), 774-780.
64. Sarafidis, P. A.; Bakris, G. L. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int., 2006, 70(7), 1223-1233. (Pubitemid 44435173)
65. Iglesias, P.; Díez, J. J. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol., 2006, 154(5), 613-621. (Pubitemid 43810845)
66. Agrawal, A.; Sautter, M. C.; Jones, N. P. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in type 2 diabetics mellitus and mild to moderate renal impairment: a post hoc analysis. Clin. Ther., 2003, 25(11), 2754-2764. (Pubitemid 37510588)
67. Defronzo, R. A.; Ferrannini, E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1991, 14(3), 173-194.
68. Ginsberg, H.; Plutzky, J.; Sobel, B. E. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucoselevel lowering. J. Cardiovasc. Risk., 1999, 6(5), 337-346. (Pubitemid 30025631)
69. Chiang, C. K.; Ho, T. I.; Peng, Y. S.; Hsu, S. P.; Pai, M. F.; Yang, S. Y.; Hung, K. Y.; Wu, K. D. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection. Diabetes Care, 2007, 30(1), 3-7.
70. Abe, M.; Okada, K.; Maruyama, T.; Maruyama, N.; Soma, M.; Matsumoto, K. Clinical effectiveness and safety evaluation of longterm pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin. Pharmacother., 2010, 11(10), 1611-1620.
71. Manley, H. J.; Allcock, N. M. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy, 2003, 23(7), 861-865. (Pubitemid 36875669)
72. Phillips, L. S.; Grunberger, G.; Miller, E.; Patwardhan, R.; Rappaport, E.; Salzman, A. Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care, 2001, 24(2), 308-315. (Pubitemid 32119130)
73. Aronoff, S.; Rosenblatt, S.; Braithwaite, S.; Egen, J. W.; Mathisen, A. L.; Schneider, R. L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care, 2000, 23(11), 1605-1611.
74. Nesto, R. W.; Bell, D.; Bonow, R. Q.; Fonseca, V.; Grandy, S. M.; Horton, E. S.; Le Winter, M.; Porte, D.; Semenkovich, C. F.; Smith, S.; Young, L. H.; Kahn, R. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the AHA and ADA. Circulation, 2003, 108(23), 2941-2948. (Pubitemid 37517824)
75. Abe, M.; Okada, K.; Kikuchi, F.; Matsumoto, K. Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. Clin. Nephrol., 2008, 70(3), 220-228.
76. Raji, A.; Seely, E. W.; Bekins, S. A.; Williams, G. H.; Simonson, D. C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care, 2003, 26(1), 172-178. (Pubitemid 36929012)
77. Drucker, D. J.; Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368(9548), 1696-1705. (Pubitemid 46048557)
78. Idris, I.; Donnelly, R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes. Obes. Metab., 2007, 9(2), 153-165. (Pubitemid 46206559)
79. Richter, B.; Banderia-Echtler, E.; Bergerhoff, K.; Lerch. C. L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane. Database. Syst. Rev., 2008, 16(2), CD006739.
80. Scheen, A. J. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab., 2010, 12(8), 648-658.
81. Herman, G. A.; Stein, P. P.; Thornberry, N. A.; Wagner, J. A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther., 2007, 81(5), 761-767. (Pubitemid 46625120)
82. Drucker, D. J. The biology of incretin hormones. Cell Metab., 2006, 3(3), 153-165.
83. Vincent, S. H.; Reed, J. R.; Bergman, A. J.; Elmore, C. S.; Zhu, B.; Xu, S.; Ebel, D.; Larson, P.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Gottesdiener, K.; Wagner, J. A.; Herman, G. A. Metabolism and Excretion of the dipeptidyl peptidase 4 inhibitor [14C]Sitagliptin in humans. Drug Metab. Dispos., 2007, 35(4), 533-538. (Pubitemid 46513255)
84. Herman, G. A.; Bergman, A.; Stevens, C.; Kotey, P.; Yi, B.; Zhao, P.; Dietrich, B.; Golor, G.; Schrodter, A.; Keymeulen, B.; Lasseter, K. C.; Kipnes, M. S.; Snyder, K.; Hilliard, D.; Tanen, M.; Cilissen, C.; De Smet, M.; de Lepeleire, I.; Van Dyck, K.; Wang, A. Q.; Zeng, W.; Davies, M. J.; Tanaka, W.; Holst, J. J.; Deacon, C. F.; Gottesdiener, K. M.; Wagner, J. A. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2006, 91(11), 4612-4619. (Pubitemid 44833446)
85. Herman, G. A.; Stevens, C.; Van Dyck, K.; Bergman, A.; Yi, B.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Wang, A. Q.; Zeng, W., Musson, D.; Winchell, G.; Davies, M. J.; Ramael, S.; Gottesdiener, K. M., Wagner, J. A. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol Ther., 2005, 78(6), 675-688. (Pubitemid 41773643)
86. Chu, X. Y.; Bleasby, K.; Yabut, J.; Cai, X.; Chan, G. H.; Hafey, M. J.; Xu, S.; Bergman, A. J.; Braun, M. P.; Dean, D. C.; Evers, R. Transport of the dipeptidyl peptidase-4 inhibtor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J. Pharmacol. Exp. Ther., 2007, 321(2), 673-683. (Pubitemid 46624514)
87. Bergman, A. J.; Cote, J.; Yi, B.; Marbuy, T.; Swan, S. K.; Smith, W.; Gottesdiener, K.; Wagner, J.; Herman, G. A. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care, 2007, 30(7), 1862-1864. (Pubitemid 47036366)
88. Chan, J. C.; Scott, R.; Arjona Ferreira, J. C.; Sheng, D.; Gonzalez, E.; Davies, M. J.; Stein, P. P.; Kaufman, K. D.; Amatruda, J. M.; Williams-Hermann, D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab., 2008, 10(7), 545-555. (Pubitemid 351850898)
89. Henness, S.; Keam, S. J. Vildagliptin. Drugs, 2006, 66(15), 1989-2001. (Pubitemid 44771935)
90. Croxtall, J. D.; Keam, S. J. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs, 2008, 68(16), 2387-2409.
91. He, Y. L.; Serra, D.; Wang, Y.; Campestrini, J.; Riviere, G. J.; Deacon, C. F.; Holst, J. J.; Schwartz, H. S.; Nielsen, J. C.; Ligueros-Saylan, M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin. Pharmacokinet., 2007, 46(7), 577-588. (Pubitemid 47025358)
92. He, H.; Yin, T. H.; Smith, H.; Batard, Y.; Wang, L.; Einolf, H.; Gu, H.; Mangold, J. B.; Fischer, V.; Howard, D. Absorption, metabolism, and excretion of [14C]Vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab. Dispos., 2009, 37(3), 536-544.
93. Christopher, R.; Covington, P.; Davenport, M.; Fleck, P.; Mekki, Q. A.; Wann, E. R.; Karim, A. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther., 2008, 30(3), 513-527. (Pubitemid 351492530)
94. Karim, A.; Covington, P.; Christopher, R.; Davenport, M.; Fleck, P.; Li, X.; Wann, E.; Mekki, Q. Pharmacokinetic of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int. J. Clin. Pharmacol. Ther., 2010, 48(1), 46-58.
95. Partley, R. E. Alogliptin: a new. highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin. Pharmacother., 2009, 10, 503-512.
96. Fura, A.; Khanna, A.; Vyas, V.; Koplowitz, B.; Chang, S. Y.; Caporuscio, C.; Boulton, D. W.; Christopher, L. J.; Chadwick, K. D. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab. Dispos., 2009;37(6):1164-1171.
97. Available from URL:http://www.ema.europa.eu/humandocs/PDFs/EPAR/onglyza/ H-1039-fr1.pdf (Accessed Jan 15, 2011).
98. Fuchs, H.; Tillement, J. P.; Urien, S.; Greischel, A.; Roth, W. Concentrationdependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J. Pharm. Pharmacol., 2009, 61(1), 55-62.
99. Fuchs, H.; Binder, R.; Greischel, A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm. Drug Dispos., 2009, 30, 229-240.
100. Blech, S.; Ludwig-Schwellinger, E.; Graefe-Mody, E. U.; Withopf, B.; Wagner, K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab. Dispos., 2010, 38(4), 667-678.
101. Huttner, S.; Graefe-Mody, E. U.; Withopf, B.; Ring, A.; Dugi, K. A. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of Bl 1356, an inhibitor of dipeptidylpeptidase 4, in healthy male volunteers. J. Clin. Pharmacol., 2008, 48(10), 1171-1178.
102. Holst, J. J. Enteroglucagon. Ann. Rev. Physiol., 1997, 59, 257-271. (Pubitemid 27142442)
103. Meier, J. J.; Gallwitz, B.; Nauck, M. A. Glucagon-like peptide and gastric inhibitory polypeptide: potential applications in type 2 dibetes mellitus. Bio. Drugs, 2003, 17(2), 93-102. (Pubitemid 36433991)
104. Nauck, M. A.; Meier, J. J.; Creutzfeldt, W. Incretins and their analogues as new antidiabetic agents. Drug News Perspect., 2003, 16(7), 413-422. (Pubitemid 37448511)
105. Nauck, M. A.; Hompesch, M.; Filipczak, R.; Le, T. D. T.; Zdravkovic, M.; Gumprecht, J. Five weeks of treatment with GLP-1 analogue liraglutide improves glycemic control and lowers body weight in subjects with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes., 2006, 114(8), 417-423. (Pubitemid 44620484)
106. Baggio, L. L.; Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132(6), 2131-2157. (Pubitemid 46711096)
107. Copley, K.; McCowen, K.; Hiles, R.; Nielsen, L. L.; Young, A.; Parkes, D. G. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr. Drug. Metab., 2006, 7(4), 367-374.
108. Linnebjerg, H.; Kothare, P. A.; Park, S.; Mace, K.; Reddy, S.; Mitchell, M.; Lins, R. Effect of renal impairment on the pharmacokinetics of exenatide. Br. J. Clin. Pharmacol., 2007, 64(3), 317-327. (Pubitemid 47283860)
109. Byetta (exenatide injection) Prescribing information. Available at http://pi.lilly.com/us/byetta-pi.pdf
110. Knudsen, L. B.; Nielsen, P. F.; Huusfeldt, P. O.; Johansen, N. L.; Madsen, K.; Pedersen, F. Z.; Thogersen, H.; Wilken, M.; Agerso, H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem., 2000, 43(9), 1664-1669. (Pubitemid 30304999)
111. Agerso, H.; Jensen, L. B.; Elbrond, B.; Rolan, P.; Zdravkovic, M. The pharmacokinetics, pharmacodinamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia, 2002, 45(2), 195-202. (Pubitemid 34208381)
112. Malm-Erjefalt, M.; Bjornsdottir, I.; Vanggaard J.; Helleberg, H.; Larsen, U.; Oosterhuis, B.; van Lier, J. J.; Zdravkovic, M. Olsen, A. K. Metabolism and excretion of the once daily human GLP-1 analog liraglutide in healthy males subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab. Dispos., 2010, 38(11), 1944-1953.
113. Juhl, C. B.; Hollingdal, M.; Sturis, J.; Jakobsen, G.; Agerso, H.; Veldhuis, J.; Porksen, N.; Schmitz, O. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes, 2002, 51(2), 424-429. (Pubitemid 34764798)
114. Chang, A. M.; Jakobsen, G.; Sturis, J.; Smith, M. J.; Bloem, C. I.; Galecki, A.; Halter, J. B. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes, 2003, 52(7), 1786-1791. (Pubitemid 36792471)
115. Degn, K. B.; Juhl, C. B.; Sturis, J.; Jakobsen, G.; Brock, B.; Chandramouli, V.; Rungby, J.; Landau, B. R.; Schmitz, O. One week's treatment with the long-acting GLP-1 derivative, liraglutide (NN2211), markedly improves 24-h glycaemia, alpha-and betacell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes, 2004, 53(5), 1187-1194. (Pubitemid 38569002)
116. Vilsboll, T.; Brock, B.; Perrild, H.; Levin, K.; Lervang, H. H.; Kolendorf, K.; Krarup, T.; Schmitz, O.; Zdravkovic, M.; Le-Thi, T.; Madsbad, S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic p-cell function and arginine-stimulated insulin secretion during hyperglycemia in patients with type 2 diabetes mellitus. Diabet. Med., 2008, 25(2), 152-156. (Pubitemid 351293400)
117. Courreges, J. P.; Zdravkovic, M.; Vilsboll, T.; Zdravkovic, M.; Lethi, T.; Krarup, T.; Schmitz, O.; Verhoeven. R.; Buganova, I.; Madsbad, S. Liraglutide, a once-daily human glucagon-like peptide-1 analogue, shows beneficial effects on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet. Med., 2008, 25(9), 1129-1131.
118. Jacobsen, L. V.; Hindsberger, C.; Robson, R.; Zdravkovic, M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol, 2009, 68(6), 898-905.
119. Young, A. Inhibition of glucagon secretion. Adv. Pharmacol, 2005, 52, 151-171. (Pubitemid 43631254)
120. Young, A. A.; Gedulin, B.; Vine, W.; Percy, A.; Rink, T. J. Gstric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia, 1995, 38(6), 642-648.
121. Gedulin, B. R.; Rink, T. J.; Young, A. A. Doseresponse for glucagonostatic effect of amylin in rats. Metabolism, 1997, 46(1), 67-70. (Pubitemid 27052027)
122. Lutz, T. A.; Mollet, A.; Rushing, P. A.; Riediger, T.; Scharrer, E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int. J. Obes. Relat. Metab. Disord., 2001, 258(7), 1005-1011. (Pubitemid 32566055)
123. Whitehouse, F.; Kruger, D. F.; Fineman, M.; Shen, L.; Ruggles, J. A.; Maggs, D. G.; Weyer, C.; Kolterman, O. G. A randomized study and open-label extension evaluating the long-term efficacy of pramlinitide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care, 2002, 25(4), 724-730. (Pubitemid 41071194)
124. Ratner, R. E.; Dickey, R.; Fineman, M.; Maggs, D. G.; Shen, L.; Strobel, S. A.; Weyer, C.; Kolterman, O. G. Amylin replacement with pramlinitide as an adjunct to insulin therapy improves longterm glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial. Diabet. Med., 2004, 21(11), 1204-1212. (Pubitemid 39472376)
125. Chapman, I.; Parker, B.; Doran, S.; Feinle-Bisset, C.; Wishart, J.; Strobel, S.; Wang, Y.; Burns, C.; Lush, C.; Weyer, C.; Horowitz, M. Effect of pramlinitide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia, 2005, 48(5), 838-848. (Pubitemid 40767975)
126. Hollander, P. A.; Levy, P.; Fineman, M. S.; Maggs, D. G.; Shen, L. Z.; Strobel, S. A.; Weyer, C.; Kolterman, O. G. Pramlinitide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care, 2003, 26(3), 784-790. (Pubitemid 36929344)
127. Riddle, M.; Brown, C.; Frias, J.; Lutz, K.; Zhang, B.; Kolterman, O.; Maier, H. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care, 2007, 30(11), 2794-2799. (Pubitemid 350083120)
128. Available from URL:http://documents.symlin.com/SYM-LIN-PI.pd (Accessed Jan 15, 2011).
129. American Diabetes Association. Standards of Medical Care in Diabetes-2008. Diabetes Care, 2008, 31, S12-S54.
130. Inaba, M.; Okuno, S.; Kumeda, Y.; Yamada, S.; Imanishi, Y.; Tabata T.; Okamura M.; Okada, S.; Yamakawa T.; Ishimura, E.; Nishizawa, Y. The Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J. Am. Soc. Nephrol., 2007, 18(3), 896-903. (Pubitemid 46434506)
131. Peacock, T. P.; Shihabi, Z. K.; Bleyer, A. J.; Dolbare, E. L.; Byers, J. R.; Knovich, M. A.; Calles-Escandon, J.; Russell, G. B.; Freedman, B. I. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int., 2008, 73(9), 1062-1068. (Pubitemid 351543905)
132. Abe, M.; Matsumoto, K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in dialysis patients with diabetes? Nat. Clin. Pract. Nephrol., 2008, 4(9), 482-483.